natgillin/translations-raw huggingface dataset:
wherein each phenyl, pyrazinyl, pyridinyl, pyridazinyl or piperazinyl of Z is optionally substituted with an R6 group; 
pri čemu je svaki fenil, pirazinil, piridinil, piridazinil ili piperazinil od Z opcijski supstituiran s R6-skupinom;
was treated with thionyl chloride (66 ml., 0.90 mole) and the resulting solution heated at reflux for 75 minutes, with provision made for trapping HC1 gas given off from the refluxing reaction solution. 
tretira se sa tionilkloridom (66 ml., 0.90 mola) i dobivena otopina zagrijava se na refluksu 75 minuta, pri čemu se osigura uklapanje HC1 plina iz refluksirajućeg reakcijskog otopine.
A therapeutic nanoparticle for use as a medicament, as claimed in any one of claims 1 to 5, wherein the hydrophobic acid is a bile acid, preferably wherein the bile acid is selected from the group consisting of chenodeoxycholic acid, ursodeoxycholic acid, deoxycholic acid, hycholic acid, beta-muricholic acid, cholic acid, lithocholic acid, an amino acid-conjugated bile acid, and combinations thereof. 
Terapijska nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što je hidrofobna kiselina žučna kiselina, po mogućnosti gdje se žučnu kiselinu bira iz skupine koju čine henodeoksikolna kiselina, ursodeoksikolna kiselina, deoksikolna kiselina, hikolna kiselina, B-murikolna kiselina, kolna kiselina, litokolna kiselina, žučna kiselina konjugirana s aminokiselinom, te njihove kombinacije.
is optionally substituted C5-C10 alkyl, wherein said optional substituents arc one to three R10 groups; 
je proizvoljno supstituiran C5-C10 alkil, pri čemu su navedeni nezavisni supstituenti jedna do tri R10 skupine;
g Propellant blend for the manufacture of a medicament packed in a container with an outlet valve for the treatment of rosacea or acne. 
Mješavinu pogonskog sredstva naznačena time da je za proizvodnju lijeka pakiranog u spremnik s ispusnim ventilom za liječenje rosacea ili akni.
Formulations generally contain a powder mix for inhalation of the compounds of the invention and a suitable powder base (carrier substance) such as lactose or starch. 
Pripravci općenito sadrže mješavinu prašaka za inhalaciju spojeva sukladno predmetnom izumu i prikladne praskaste baze (nosiva tvar), poput laktoze ili škroba.
The antisense oligonucleotide of claim 5, wherein the oligonucleotide is chemically linked to a polyethylene glycol molecule. 
Antisens oligonukleotid prema zahtjevu 3, naznačen time da je oligonukleotid kemijski vezan na polietilen-glikolski lanac.
A monolithic radiant panel configured to provide one of heating and cooling in an indoor area, the monolithic radiant panel comprising: 
Sustav s monolitnim radijativnim panelom, konfiguriran za omogućavanje grijanja i hlađenja u zatvorenom prostoru, gdje sustav s monolitnim radijativnim panelom sadrži monolitni radijativni panel (100), gdje monolitni radijativni panel (100) sadrži:
A packaging and a device for manual rolling of cigarettes containing smoker's articles like cigarette sheets, cigarette filters, filter sheets, matches, lighters, tobacco and the like as well as an article that may as well be used as an advertising material is characterized in that a base side is divided with folding lines into two smaller sides with a narrow band therebetween; that the intermediate band is terminated at both sides each time with two triangular parts, which provides for creating a handy table for rolling cigarettes; that the narrow band is foldably divided in a way that the external parts are embraced by triangular folded corners of smaller sides; that while the device is in use, the packaging is opened and put onto a support in a way that small sides are lifted upwards, that the triangular sides on both sides of the narrow band are then pushed upwards to create bulges; that the two bulges each from its side stop the narrow side and prevent the content from falling from the support. 
PATENTNI ZAHTJEVI Pakiranje i uređaj za ručno motanje cigareta, koje/i sadrži pušačke proizvode kao što su cigaretni papiri, cigaretni filteri, filterski papiri, šibice, upaljači, duhan i slično, kao 1 proizvod koji se također može koristiti kao reklamni materijal, naznačen/o time, da je podna strana podijeljena pregibnim linijama u dvije manje strane s uskim pojasom između njih; te je pritom srednji pojas završen s obje strane svaki puta s dva trokutasta komada, što omogućava stvaranje praktičnog stolića za motanje cigareta; pri čemu je uski pojas pregibno podijeljen na takav način, da su vanjski dijelovi obavijeni trokutastim pregibnim uglovima od manjih strana; a za vrijeme uporabe uređaja, pakiranje je otvoreno i postavljeno kao oslonac na takav način, da su male strane podignute prema gore, dok su trokutaste strane s obje strane uskog pojasa tada gurnute prema gore za stvaranje izbočenja; pri čemu dva izbočenja, svako sa svoje strane, zaustavljaju usku stranu i sprečavaju da sadržaj ispadne iz oslonca.
wherein the atomized treatment agent (52) is delivered by the conduit (70) from the pressurized container (54) to the interior location of the closed mechanical system; the delivery system characterized by: 
(c) pri čemu se atomizirano sredstvo za obradu (52) dovodi putem vodilice (70) iz spremnika pod tlakom (54) do mjesta u unutrašnjosti zatvorenog mehaničkog sustava; te je sustav za dovođenje naznačen time da:
A high-energy feed pellet based on natural materials, wherein the total fat percentage of the feed pellet is more than 15 wt.%, characterised in that the feed pellet has a density of at most 700 g/l, and a swelling capacity of at least 40 ml after 30 minutes, based on 50 g of feed pellets. 
HR P20131186 T1 PATENTNI ZAHTJEVI Visoko-energetske hranjive pelete na bazi prirodnih materijala, gdje je ukupni postotak masti u hranjivim peletama veći od 15 tež.%, naznačeno time što hranjive pelete imaju gustoću najviše 700 g/l, i kapacitet bubrenja od najmanje 40 ml nakon 30 minuta, na temelju 50 g hranjivih peleta.
When the reactive functional group on the sugar or sugar derivative is an amino group (which can be situated at any position of the sugar), a carbamate linkage to rapamycin results and the resulting linker is a carbonyl group. 
Kad je reaktivna funkcionalna grupa na šećeru ili šećernom derivati amino-grupa (koja može biti smještena na bilo kojem položaju šećera), nastaje karbamatna veza s rapamicinom, a nastali veznik je karbonilna grupa.
A tablet comprising apixaban and a pharmaceutically acceptable diluent or carrier, wherein the formulation exhibits dissolution properties such that an amount of the drug equivalent to at least 77% dissolves within 30 minutes, wherein the dissolution test is performed in an aqueous media buffered to a pH range 1 to 7.4 and controlled at 37° C. 
Tableta ili kapsula koja sadrži farmaceutsku kompoziciju, gdje farmaceutska kompozicija sadrži apiksaban i farmaceutski prihvatljiv razrijeđivač ili nosač, gdje je apiksaban u obliku tvari i kristalnom obliku i pojedinačne tvari apiksabana, bilo da tvari postoje zasebno ili u aglomeratu, imaju D90 jednak ili manji od 89 µm kao što je mjereno raspršivanjem laserske svjetlosti.
A compound deoxyactagardine B (7-amino-1-heptylamide monocarboxamide), and pharmaceutically acceptable salts thereof. 
Spoj, naznačen time, da je to deoksiaktagardin B (7-amino-1-heptilamid monokarboksamid), i njegove farmaceutski prihvatljive soli, hidrati i solvati.
In accordance with some forms of embodiment, the star centers of the individual power phase sub-modules 34R, 34S, 34T are connected to each other to the neutral N. In this way, even if a phase sub-module 34R, 34S, 34T switches off, it is possible in any case to have a modulation with the expected number of impulses. 
Uređaj prema patentnom zahtjevu 1, naznačen time što je svaki od faznih pod-modula (34R, 34S, 34T) spojen sa zvjezdastim spojem i zvijezda je središte pojedinačnih pod-modula (34R, 34S, 34T) međusobno spojenih na nulu (N).
The present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal activity of GSK3B. 
Ovaj izum odnosi se na spojeve korisne kao aktivni sastojak lijeka za sprječavanje i/ili terapijsko liječenje neurodegenerativnih bolesti uzrokovanih abnormalnom aktivnošću GSK3P.
The process of item 57, wherein the density of the cured extended release matrix formulation in comparison to the density of the uncured extended release matrix formulation decreases by at least about 0.5%, preferably at least about 0.7%. 
Postupak prema zahtjevu 57, naznačen time da je gustoća stvrdnute formulacije matrice s produljenim otpuštanjem u usporedbi s gustoćom nestvrdnute formulacije matrice s produljenim otpuštanjem smanjena za barem oko 0.5%, poželjno barem oko 0.7%.
applying a solid mineral alkaline in powder form to the particles of step a) in order to react with the grasping layer of the particles to coat the acidified particle surface; wherein the stoichiometric ratio of solid mineral alkaline in powder form to concentrated mineral acid is equal to or more than 5:1. More in general, a particulate ammonium nitrate-based fertilizer, comprising ammonium nitrate-based particles, is provided, wherein the ammonium nitrate-based particles comprise an inorganic coating comprising the reaction product of a liquid concentrated mineral acid with a water content of less than 50 weight%, a solid mineral alkaline in powder form, and ammonium nitrate, wherein the stoichiometric ratio of solid mineral alkaline in powder form to concentrated mineral acid to arrive at said coating is equal to or more than 5:1. 
HR P20180796 T1 PATENTNI ZAHTJEVI Postupak za dobivanje anorganskog premaza na česticama na bazi amonijeva nitrata, a postupak obuhvaća korake: a) primjenu tekuće koncentrirane mineralne kiseline s udjelom vode manjim od 50 % težinskih udjela na čestice, kako bi se barem solubilizirao amonijev nitrat na vanjskoj površini čestica tako da se dobije kiselinski sloj za zahvaćanje čestica i b) primjenu krute mineralne lužine u praškastom obliku na čestice 1z koraka a), kako bi reagirale sa zahvatnim slojem čestica 1 na taj se način premazala zakiseljena površina čestica; naznačen time, da je stehiometrijski omjer krute mineralne lužine u prahu i koncentrirane mineralne kiseline jednak ili veći od 5: 1.
The use of a compound of formula I as its dihydrochloride salt in the manufacture of a medicament for treating vasomotor disturbances in a perimenopausal or postmenopausal woman in need thereof, wherein the medicament is a unit dosage form comprising from 0.9 to 1.1 mg, from 2.2 to 2.8 mg, from 4.4 to 5.6 mg or from 9 to 11 mg of said compound, and wherein the method comprises the once-daily administration of said unit dosage form to the patient. 
< Z1 "a "e N i e 9. G u proizvodnji lijeka za liječenje vazomotornih poremećaja u peri-menopauzalnih ili postmenopauzalnih žena kojima je to potrebno, gdje je lijek jedinični dozirni oblik koji sadrži od 0.9 do 1.1 mg, od 2.2 do 2.8 mg, od 4.4 do 5.6 mg ili od 9 do 11 mg tog spoja, i gdje postupak obuhvaća primjenu tog jediničnog dozirnog oblika bolesnici jednom dnevno.
The crystalline form t of rifaximin according to claim 1, characterized by a tetragonal crystal system, the space group is P41212 and the unit cell parameters are a=b=16.51 (1) Å; c=36,80(1) Å; a=B=Y= 90°; V= 10027(1) Å3. 
Kristalni oblik T rifaksimina u skladu s patentnim zahtjevom 1, naznačen time što ima tetragonski kristal sustav, gdje je prostorna skupina P41212, a parametri jedinične ćelije su a=b=16,51 (1) A; c=36,80(1) A; o=f=y= 90%; V= 10027(1) A3.
Use of a polyclonal antibody that inhibits the ability of the allergen Fel D1, Can F1, Der p1, Der p2, Bla g1, Bla g2, Asf 1, Ara hl, Ara h2, or Ara h3 to bind to mast cells, to reduce an allergic response in a human, a feline or a canine predisposed to having an allergic response to said allergen comprising minimizing exposure to the allergen by contacting a source of the allergen in the environment with a composition containing said polyclonal antibody. 
Postupak radi slabljenja ili sprječavanja alergijskog odgovora kod životinje sklone pojavi alergijskog odgovora na alergen Fel D1 u okolišu, naznačen time što se obuhvaća stavljanje u kontakt izvora alergena Fel D1 u okolišu s pripravkom koji sadrži molekulu koja sadrži protutijelo protiv Fel D1 koje inhibira sposobnost vezanja alergena Fel D1 na IgE prisutan na mastocitima kod navedene životinje sklone pojavi alergijskog odgovora na alergen Fel D1.
The lock could also be of the kind, which must be partly damaged in order to remove the element. 
Blokada može također biti takve vrste koja mora biti djelomično oštećena ako se uklanja element.
Potassium dihydrogen phosphate 
Kalij dihidrogen fosfat
water in an amount from 10.0 to 40.0% by weight of the composition, 
vode u količini od 10,0 do 40,0 % masenog udjela pripravka,
In particular, this housing is a watertight housing, at least with respect to the hull, in all the walls thereof, except for an opening that opens externally to the hull of the ship or platform. 
- kućište (3) je nepropusno kućište u odnosu na trup unutar zidova (5), osim otvora (6) koji se otvara izvan trupa (4) broda ili platforme;
Isolation by centrifugation follows. Letermovir according to Formula (I), which is in the amorphous state, obtainable by a precipitation process for isolating amorphous Letermovir, characterized by precipitation of said amorphous Letermovir from the water miscible solvents acetone or acetonitrile into excess stirred water, following isolation via filtration or centrifugation of the Letermovir obtained. 
Letermovir prema formuli (1), Forenula (I), koji je u amorfnom stanju, dobavljiv postupkom taloženja za izoliranje amorfnog Letermovira, naznačen time što taloženje spomenutog amorfnog Letermovira iz otapala koja se mogu miješati s vodom acetona ili acetonitrila u suvišak miješane vode, nakon izolacije pomoću filtracije ili centrifugacije dobivenog Letermovira.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) klorotalonil.
Compounds of formula (I): 
Spoj opće formule (I):
Composition for use according to claim 1, wherein the tegafur is administered at a dose of between 20 mg/m2 to 45 mg/m2 twice daily. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da se tegafur daje u dozi od 20 mg/m? do 45 mg/m* dva puta dnevno.
The pharmaceutical composition of claim 1, comprising a structure compound of formula (Ia): wherein: 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 6, koja je odabrana od spoja sa formulom (Ia):
a first protrusion and a second protrusion arranged on a location selected from the group consisting of the inner surface of the insertion tube, the outer surface of the insertion tube, the inner surface of the slider and the outer surface of the slider, wherein the first and second protrusions are arranged so as to move the first and second locking parts to a second position when moving the insertion tube. The locking means could also be welding, gluing, cutting, knot or adhesion. 
prvo izbočenje (19a) i drugo izbočenje (19b) smješteno na položaju izabranom iz grupe koja obuhvaća unutarnju površinu cjevčice za umetanje, vanjsku površinu cjevčice za umetanje, unutarnju površinu klizača i vanjsku površinu klizača, pri čemu su prvo i drugo izbočenje (19a, 19b) smješteni tako da pomiču prvi u drugi dio za zaključavanje (184, 18b) u drugi položaj kada se pomiče klizač i/ili cjevčica za umetanje.
Cutting the different pieces of the fabric of the garment, comprising said fabric at least a natural non-elastic fibre material, a first synthetic fibre material and a second elastic synthetic fibre material, being the fibres of the synthetic fibre materials twisted together, and characterized because it further comprises the steps of: 
Rezanje različitih dijelova tkanine odjevnog predmeta, pri čemu navedena tkanina sadržava barem jedan materijal od prirodnih neelastičnih vlakana, prvi materijal od sintetičkih vlakana 1 drugi elastični materijal od sintetičkih vlakana, pri čemu su vlakna materijala sintetičkih vlakana isprepletena zajedno i, naznačen time, da obuhvaća 1 sljedeće korake;
For example, the compound of formula (I), where R6 is C1-C8-alkyl, which is conveniently in solution in a polar organic solvent or a mixture thereof with water, may be reacted with an aqueous inorganic base, such as NaOH or LiOH to hydrolyse the ester group; where the base is NaOH, the reaction may be carried out at a temperature of 10-40° C., conveniently ambient temperature, while when the base is LiOH the reaction may be started at −5° C. to 5° C. and then continued at 10-40° C., conveniently ambient temperature. 
Na primjer, spoj formule (T), u kojoj R" je C,-Cg-alkil, koji je uobičajeno otopljne u polarnom organskom otapalu ili u njegovooj mješavini s vodom, može reagirati s vodenom anorganskom bazom, kao što je NaOH ili LiOH s hidrolizom esterske skupine; ako je baza NaOH, reakciju se može provesti pri temperaturi od 10-40*C, prikladno pri sobnoj temperaturi, dok u slučaju da je baza LiOH, reakcija može započeti pri -5"C do S'Ci zatim se nastavi pri 10-40"C, prikladno pri sobnoj temperaturi.
After placing and covering the sheetlike part with a further foil layer, the pressure in the space between the molding wall and the air-tight covering is adjusted to a first value d1, which is lower than the ambient pressure, after which the pressure within the channel parts is adjusted to a second value d2, which is lower than the first value d1. 
Nakon stavljanja i pokrivanja tog dijela sličnog listu s daljnjim slojem folije, pritisak u prostoru između stijenke kalupa i neprodušnog pokrova se namjesti na prvu vrijednost dl, koja je niža od pritiska okoline, nakon čega se pritisak unutar dijelova kanala namjesti na drugu vrijednost d2, koja je niža od prve vrijednosti dl.
The process of claim 28 further comprising the step of adding an unsubstituted or a substituted 1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid amide or 1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid amide, an excess amount of a suitable base, and a diaryldisulfide or a diheterocycledisulfide to a suitable solvent and heating to afford a compound of formula (I) wherein R1 is hydrogen. 
Postupak u skladu s patentnim zahtjevom 28, koji se dalje sastoji u koraku dodavanja nesupstituiranog ili supstituiranog amida 1H-pirolo[3,2-b]piridin-2-karboksilne kiseline, amida 1H-pirolo[3,2-c]piridin-2-karboksilne kiseline ili amida 1H-pirolo[2,3-c]piridin-2-karboksilne kiseline, suvišne količine pogodne baze, te diaril-disulfida ili diheterocikl-disulfida u pogodno otapalo, te grijanju kako bi se dobilo spoj formule (I), gdje R; je vodik.
The fibre product (2, 2.1, 2.2, 2.3) according to claim 1, characterised in that the activated charcoal (6) is at least partially formed from a vegetable material, in particular from coconut husks. 
Upotreba u skladu s patentnim zahtjevom 2, naznačena time što se aktivni ugljen (6) u najmanju ruku dijelom dobiva iz biljnog materijala. Upotreba u skladu s patentnim zahtjevom 3, naznačena time što se aktivni ugljen (6) u najmanju ruku dijelom dobiva iz kokosovih ljuski.
combining an isolated monospecific bivalent anti-EGFR antibody comprising two heavy chains of SEQ ID NO: 199 and two light chains of SEQ ID NO: 200 and an isolated monospecific bivalent anti-c-Met antibody comprising two heavy chains of SEQ ID NO: 201 and two light chains of SEQ ID NO: 202 in a mixture of about 1:1 molar ratio; 
kombiniranje izoliranog monospecifičnog dvovalentnog anti-EGFR protutijela koje sadrži dva teška lanca SEQ ID NO: 199 i dva laka lanca SEQ ID NO: 200 i izolirano monospecifično dvovalentno anti-c-Met protutijelo koje sadrži dva teška lanca SEQ ID NO: 201 i dva laka lanca SEQ ID NO: 202 i smjesu u molarnom odnosu oko 1:1;
An optoelectronic device as claimed in any preceding claim, wherein the first semiconductor material (316) is a p-type semiconductor material and the second semiconductor material (317) is an n-type semiconductor material. 
Optoelektronički uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi poluvodički materijal (316) je p-tip poluvodičkog materijala, a drugi poluvodički materijal (317) je n-tip poluvodičkog materijala.
A CAR according to para 1 or 2 wherein the spacer lacks the intracellular domain of LNGFR. 
CAR prema patentnom zahtjevu 1 naznačen time što razmaknici nedostaje unutarstanična domena LNGFER.
The G-2-MePE for the use of Claim 1 or Claim 2, wherein said ASD is selected from the group consisting of autism, Fragile X Syndrome, Rett Syndrome (RTT), Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS), and Pathological Demand Avoidance (PDA). 
G-2-MePE za primjenu prema zahtjevu 1 ili zahtjevu 2, naznačen time, što je spomenuti poremećaj autističnog spektra odabran iz grupe koja se sastoji od autizma, sindroma fragilnog X kromosoma, Rettovog sindroma (RTT), autističnog poremećaja, Aspergerovog sindroma, dječjeg dezintegrativnog poremećaja 1 pervazivnog razvojnog poremećaja koji nije drugačije specificiran (PDD-NOS) te patološkog izbjegavanja zahtjeva (PDA).
roller compacting the formulation prepared during step (a) with a compaction force comprised between 10 and 16 KN, 
(b) sabijanja valjkom formulacije pripremljene tijekom koraka (a) silom sabijanja obuhvaćenom između 10 i 16 KN; te
According to a further embodiment of the present invention, it is preferred that repeating the first message occurs only after a predetermined second time interval after initially or previously sending the first message. 
Metoda u skladu s patentnim zahtjevom 5, naznačen time da se ponavljanje prve poruke odvija tek nakon unaprijed određenog drugog vremenskog intervala (T2) nakon inicijalno ili prethodnog slanja prve poruke.
The multipurpose airway device as claimed in any one of the preceding claims, in which a separate hypopharyngeal tube is provided to fit snugly into the tubular airway body and connector and to protrude beyond the end of the tubular airway body so that in use the tube can be passed beyond a patient's epiglottis and into the hypopharynx thereby making the device a "hands free" airway. 
Višenamjenski uređaj za disanje sukladno bilo kojem prethodnom zahtjevu, u kojem se posebna hipofaringealna cjevčica bez problema uvodi u cjevasto tijelo i spojku, a zatim provlači kroz to tijelo kako bi prilikom upotrebe prošla iznad epiglotisa pacijenta i ušla u njegovo/njezino ždrijelo i pritom omogućuje disanje bez dodatne pomoći stručnog osoblja.
Garment, according to claim 1 characterized in that it is a pair of stretchy denim fabric trousers. 
Odjevni predmet, u skladu s patentnim zahtjevom 1, naznačen time, da je to par hlača od elastične traper tkanine.
Thus, the invention also relates to the use of a compound according to the invention for the manufacture of a medicament for the treatment of androgen insufficienc y or a medicament for testosterone replacement. 
HR P20070492 T3 Prema tome, ovaj izum se također odnosi na upotrebu spoja prema ovom izumu u proizvodnji medikamenta za liječenje androgenske insuficijencije ili medikamenta za testosteronsku zamjensku terapiju.
The following compounds were prepared similarly to the method described in Example 1 and were characterised in the form indicated, starting from the appropriate N-substituted dihydropyridine oxalate and H2/Pd. 
Slijedeći spojevi načinjeni su na sličan način kao što je opisano u Primjeru 1 i okarakterizirana su u označenom obliku, polazeći od odgovarajućeg N-supstituiranog dihidropiridin oksalata i H/Pd.
After the mannitol and buffer were added, the IL-2 concentration in the formulated solution was determined by measuring the absorbance at 280nm. 
Nakon što se dodalo manitol i pufer, IL-2 koncentracija u formuliranoj otopini određena je mjerenjem apsorbancije pri 280 nm.